Alterity Therapeutics to Speak at Maxim Healthcare Conference
Ticker: PRNAF · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, filing-update, registration-statement
TL;DR
ALT to present at Maxim Healthcare Virtual Conference, filing incorporated into S-8/F-3 registrations.
AI Summary
Alterity Therapeutics Limited announced on October 15, 2024, that it will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Conference. This event is being incorporated by reference into several of the company's existing Registration Statements on Form S-8 and Form F-3.
Why It Matters
Participation in industry conferences like the Maxim Healthcare Virtual Conference provides Alterity Therapeutics with a platform to share updates and engage with investors and industry professionals, potentially increasing visibility and interest in the company's development stage enterprise.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Maxim Healthcare Virtual Conference (company) — Event
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed by Alterity Therapeutics Limited for the month of October 2024, and it incorporates by reference an announcement that the company will participate in the 2024 Maxim Healthcare Virtual Conference.
Which registration statements is this filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What specific event is Alterity Therapeutics participating in?
Alterity Therapeutics is participating in a fireside chat at the 2024 Maxim Healthcare Virtual Conference.
What is Alterity Therapeutics Limited's principal executive office address?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Yes, Alterity Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 203 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-10-15 08:00:06
Filing Documents
- ea0217518-6k_alterity.htm (6-K) — 14KB
- ea021751801ex99-1_alterity.htm (EX-99.1) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-087483.txt ( ) — 39KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 15, 2024 2